Lybalvi 5-10 MG tablet UU 30S
Ended Awarded Last action
- Contract number
- SPE2DR26F9CTW
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $15,345
Award facts
- Contract value 100% obligated
- $15,345.34 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $15,345.34 to AmerisourceBergen Drug Corp for LYBALVI 5-10 mg tablets (30-count units) on January 7, 2026, with an ultimate completion date of January 8, 2026. This firm fixed-price delivery order represents a non-set-aside competitive award and will be performed at the contractor's location in Conshohocken, Pennsylvania. The award is issued under AmerisourceBergen Drug Corp's parent company, Cencora, Inc., which holds a $999.99 billion indefinite delivery contract with DLA Troop Support Medical extending through December 31, 2031, serving as the primary vehicle for pharmaceutical and medical supply distribution to military healthcare programs globally.
This delivery order falls within the broader context of federal pharmaceutical procurement for military and defense healthcare systems. AmerisourceBergen, operating as a subsidiary of Cencora, Inc., is a major pharmaceutical distributor that supplies a comprehensive range of medications across multiple therapeutic domains to support military treatment facilities and veteran healthcare programs. The award of LYBALVI, a psychiatric medication used in schizophrenia and bipolar disorder treatment, reflects the ongoing medical supply needs of the Defense Health Agency and broader military healthcare infrastructure. The non-set-aside competitive award designation indicates the contract was awarded through full and open competition, demonstrating the contractor's capability to meet federal procurement standards for essential pharmaceutical commodities.
Quick answers
Who was awarded contract SPE2DR26F9CTW?
SPE2DR26F9CTW was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 7, 2026.
How much is contract SPE2DR26F9CTW worth?
The government has obligated $15,345 on SPE2DR26F9CTW.
Is contract SPE2DR26F9CTW an order under another contract?
Yes. SPE2DR26F9CTW is a delivery order under SPE2DR25D1017, an indefinite delivery contract.
Was contract SPE2DR26F9CTW competed?
The extent of competition for SPE2DR26F9CTW was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award